From: Effect sizes in ongoing randomized controlled critical care trials
Trial name | Effect size (%) | Sample size | ||
---|---|---|---|---|
Median largest absolute mortality reduction considered plausible (IQR, range) | Absolute mortality reduction postulated by trialists | Size required to detect median largest effect size considered plausible | Actual | |
A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine in Intensive Care Patients | 5 (2–6, 0–23)) | 10 | 3186 | 800 |
ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients with Septic Shock | 5 (3–10, 0–33) | 5 | 3556 | 3800 |
Early Spontaneous Breathing in ARDS | 5 (2–10, 0–35) | 10 | 2748 | 700 |
Non-sedation versus Sedation with a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation | 5 (3–15, 0–39) | 10 | 2904 | 700 |
Stress Ulcer Prophylaxis in the Intensive Care Unit | 3 (1–5, 0–25) | 5 | 8388 | 3350 |
The Augmented versus Routine Approach to Giving Energy Trial | 3 (1–5, 0–25) | 3.95 | 6266 | 4000 |
The SuDDICU Cluster RCT of Antibiotic Prophylaxis in Critical Illness | 5 (3–9, 0–24) | 3.5 | Not calculateda | 24,000 |
Ticagrelor in Severe CAP | 3 (1–5, 0–33) | 11 | 7522 | 568 |
Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double-blind, placebo-controlled trial | 3 (2–5, 0–10) | 2.5 | 3624 | 8000 |
Tranexamic acid for the treatment of significant traumatic brain injury: an international, randomised, double-blind, placebo-controlled trial | 4 (2–5, 0–10) | 3 | 3868 | 10,000 |